Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
GRID2 Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, delta-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRID2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MLNR Biologics Sequence Review Report 2026: Motilin receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MLNR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
FFAR2 Biologics Sequence Review Report 2026: Free fatty acid receptor 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
P2RX6 Biologics Sequence Review Report 2026: P2X purinoceptor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of P2RX6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GRIN2D Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 2D Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRIN2D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
GRM6 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRM6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LEPROT Biologics Sequence Review Report 2026: Leptin receptor gene-related protein Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of LEPROT protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
EPHB6 Biologics Sequence Review Report 2026: Ephrin type-B receptor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EPHB6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
PGRMC2 Biologics Sequence Review Report 2026: Membrane-associated progesterone receptor component 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of PGRMC2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
LDLRAD4 Biologics Sequence Review Report 2026: Low-density lipoprotein receptor class A domain-containing protein 4 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of LDLRAD4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
MUSK Biologics Sequence Review Report 2026: Muscle, skeletal receptor tyrosine-protein kinase Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MUSK protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Latest Hotspot
8 min read
NCR3 Biologics Sequence Review Report 2026: Natural cytotoxicity triggering receptor 3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of NCR3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.